EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse

Binayak Rimal, Ruth A Howe, Chandra M Panthi, Wen Wang, Gyanu Lamichhane iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01351-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Binayak Rimal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MicuRx Pharmaceuticals, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium abscessus (Mab ) is an opportunistic pathogen common in patients with lung comorbidities and immunosuppression. There are no FDA-approved treatments, and current treatment has a failure rate exceeding 50%. The intravenous oxaborole MRX-6038 is active against Mab . This study evaluated MRX-5, the oral prodrug, against five Mab isolates in a mouse lung infection model. MRX-5 showed dose-dependent efficacy, with 15 and 45 mg/kg doses comparable to the standard of care, supporting progression to clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusMycobacterium Infections, NontuberculousAnimalsMiceAnti-Bacterial AgentsLungProdrugsDisease Models, AnimalAdministration, OralFemaleMicrobial Sensitivity TestsBoron Compounds

Stichwörter der Autor:innen

MRX-5Mycobacterium abscessus

Substanzen

Anti-Bacterial AgentsProdrugsBoron Compounds

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • MicuRx Pharmaceuticals, Inc., Foster City, California, USA.
  • Center for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

ORCID-Profile: Gyanu Lamichhane

Förderung

  • MicuRx Pharmaceuticals, Inc

Zitieren

APA

Rimal, B., Howe, R. A., Panthi, C. M., Wang, W., & Lamichhane, G. (2024). Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01351-24

Vancouver

Rimal B, Howe RA, Panthi CM, Wang W, Lamichhane G. Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01351-24

BibTeX
@article{Rimal2024,
  author = {Rimal, Binayak and Howe, Ruth A and Panthi, Chandra M and Wang, Wen and Lamichhane, Gyanu},
  title = {Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01351-24}
}
Kostenlos starten →